2 innovative scientific platforms

Ipsen is renowned for its expertise in toxins and peptides. The Group operates two technological platforms. Both are centers of excellence in these fields and both have substantial potential for differentiation. We also draw on this expertise to use the synergies generated between toxins and peptides in hybrid molecules to obtain targeted secretion inhibitors (TSIs). With their unique properties, these molecules offer potential in the treatment of neuromuscular, endocrine and proliferative disorders, as well as for pain.


Excellent technological platforms: toxins and peptides

> €200 M

Expenditure in R&D in 2016

Last update 10/04/2017